SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, currently based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications. In September 2009, SIGA Technologies received a $1.6 million research fund from the National Institutes of Health ("NIH") for its broad-spectrum antiviral candidates. In August 2011, SIGA Technologies was awarded a $7.7 million grant from the National Institutes of Health (NIH) to develop an antiviral drug for treating and preventing Lassa fever and others of arenavirus origin. That year, it sealed a contract worth over $400 million to sell its antiviral drug TPOXX to the United States Biomedical Advanced Research and Development Authority (BARDA) for the purpose of its development and distribution. Also in 2011, it was ordered to pay $232 million in damages in a legal dispute with PharmAthene over rights to the smallpox drug tecovirimat. More information...
According to PR-model, siga.com is ranked 485,849th in multilingual Wikipedia, in particular this website is ranked 386,233rd in English Wikipedia.
The website is placed before beercoasters.it and after nameecho.com in the BestRef global ranking of the most important sources of Wikipedia.
